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Decamethylcyclopentasiloxane (D5) is a cyclic siloxane used in the production of industrial and con-
sumer products. Four groups of 60 Fischer-344 female rats were analyzed for uterine endometrial
adenocarcinoma (inhalation study with exposure levels in ppm/number of observed cases: 0/0, 10/1, 40/
0, and 160/5) by exact regression (logistic, Poisson), the max poly-3 trend test, and a random effects
probit model. When comparing the 160 ppm group to controls after 24 months, the incidence of ade-
nocarcinomas was elevated (borderline signiﬁcant); it was signiﬁcant when all exposure levels were
included. Four sets of (historical) control groups were formed, with varying heterogeneity. The effect of
D5 was either signiﬁcant or borderline signiﬁcant when comparing all control sets to the 160 ppm group.
When considering all exposure groups using any of the analysis methods, a signiﬁcant effect was
observed when the high dose group was included in the analysis; the effect was not signiﬁcant when the
high dose group was not included. The evidence tends to support the conclusion that D5 at the highest
dose level (160 ppm) results in an increased incidence of adenocarcinomas. However, it is important to
verify any potential effect through a biological investigation.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Decamethylcyclopentasiloxane (D5), a low-molecular-weight
cyclic siloxane, is used in the production of industrial and con-
sumer products with potential exposure to consumers, the general
public and manufacturing workers.
As described in the companion paper, Jean et al. (2015) con-
ducted a study to evaluate the possible long-term toxic and onco-
genic effects of D5 on Fischer-344 rats. Four groups of 96 males and
96 females were formed, one for each of the D5 exposure levels: 0,
10, 40, and 160 ppm. All animals within a group were placed in a
chamber, and the animals’ positions within the chamber were
rotated on a weekly basis. The rats were exposed for 6 h/day, 5nstitute of Food and Agricul-
University of Florida, Gaines-
n open access article under the Cdays/week, to D5 vapor by whole body inhalation route. Four
subgroups of rats were formed within an exposure level: (A) 6
months of exposure, (B) 12 months of exposure, (C) 12 months of
exposure followed by 12 months of recovery, and (D) 24 months of
exposure. The 240 females in the 24-month exposure subgroup
(subgroup D), which had 60 female rats at each of the four exposure
levels, is the focus of this work.
During the D5 24-month exposure study, mortality, clinical
signs, ophthalmoscopical changes, and body weights were recor-
ded. Clinical measurements of hematology, clinical biochemistry,
and urinalysis were performed after 3, 6, and 12 months, and he-
matology was performed after 14 months. Terminal macroscopic
examination and organ collection was conducted on all animals.
Organs were weighed at scheduled necropsies. Lungs, liver, kid-
neys, nasal cavities, gross lesions, and tissue masses were
examined.
Unexpectedly, ﬁve cases of endometrial uterine adenocarci-
noma occurred in the highest dose group. Only one additional caseC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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10 ppm (Table 1).
The incidence of endometrial adenocarcinomas within the
highest dose group (160 ppm) was compared to that within the
control group using the Fisher exact test. Consistent with the
approach used by the National Toxicology Program (NTP), a one-
sided Fisher exact test was used to assess whether the highest
exposure level (160 ppm) group had an increase in the incidence of
spontaneous adenocarcinomas compared to the controls. The p-
value for this one-sided test was 0.0287, indicating a signiﬁcant
increase in spontaneous adenocarcinomas for this highest exposure
group. In a review of the study protocol, the concernwas raised that
the stated hypotheses would indicate that a two-sided, not a one-
sided, test was more appropriate. The two-sided Fisher exact test
comparing the incidence of spontaneous adenocarcinomas in the
highest exposure group to the control group produced a p-value of
0.0573. The one-sided test was signiﬁcant and the two-sided test
was not signiﬁcant, but close to the 0.05 signiﬁcance level. In either
case, sufﬁcient concerns were raised to lead researchers to examine
the full D5 24-month study. A statistically signiﬁcant increase in
spontaneous endometrial adenocarcinomas was found, with the
increase appearing to be due to the highest exposure level
(160 ppm). The biological mechanism that could explain such an
effect was explored (Dekant and Klaunig, 2015). When no apparent
mechanismwas identiﬁed, a re-evaluation of the statistical analysis
was conducted. Given the large number of statistical tests con-
ducted in the original analysis, could the observed result be a
spurious one? The purpose of this work is to provide a full analysis
of incidence of endometrial adenomas, adenocarcinomas and
combined adenomas and adenocarcinomas based on data from the
D5 24-month exposure study.
1.1. Initial analyses
Endometrial adenomas/adenocarcinomas were believed to be
relatively rare based on a review of the NTP data on Fischer-344 rats
(Haseman et al., 1998). As indicated in Table 1, no adenoma was
observed in any of the animals in the D5 study. Five of the 60
Fischer rats receiving the highest dose (160 ppm) had uterine
endometrial adenocarcinomas; only one adenocarcinoma was
observed in all of the other dose groups. Smith et al. (2005) and
Casella et al. (2012) considered various analyses. Since then, a
correction was made in the data because a spontaneous adenoma
recorded for an animal in the 10 ppm exposure group was later
determined to be a focal glandular hyperplasia (Regan, 2014). As in
Jean et al. (2015), we use the revised data and begin by summari-
zing the earlier analyses. Although the incidences of adenomas and
adenocarcinomas were analyzed separately as well as combined in
the original analyses, no adenomas were observed in this study.
Thus, only the adenocarcinomas will be considered here. Further,
all analyses are fully described so that this paper can stand alone in
the presentation of the statistical analyses.
1.2. Fisher exact tests and Poisson regression
Fisher's exact test was originally developed to test whether theTable 1
Adenoma/adenocarcinomas observed in D5 24-month exposure study.
Dose Total animals Study length unit
0 60 738
10 60 738
40 60 738
160 60 738proportion of observations with a positive response is the same for
each of two treatments, given the number of observations for each
treatment and the total number of positive responses. Under the
null hypothesis that the proportions of positive responses are equal
for two treatment groups, the test statistic is a random observation
from a hypergeometric distribution, and the p-value of the test can
be determined exactly; that is, computation of the p-value does not
depend on asymptotic (large sample) theory.
When considering all dose levels, the p-value associated with
the test of no differences in the proportions with adenocarcinomas,
the test statistic is 0.0166 (see Table 2). However, when the highest
dose level (160 ppm) is not included in the analysis (leaving the
control, 10 ppm, and 40 ppm dose groups), the proportions
expressing adenocarcinomas are not signiﬁcantly different. Further,
as noted earlier, the incidence of adenocarcinomas is close to sig-
niﬁcant (p ¼ 0.0573) when using a two-sided test and signiﬁcant
(p ¼ 0.287) using a one-sided test.
When the incidence is low, slight changes in the data can result
in a substantial change in the p-value associated with a test. For
example, the 12-month exposure/12-month recovery control group
in the D5 study had one adenocarcinoma, instead of the 0 tumors
observed in the 24-month exposure control group. If there had
been one adenocarcinoma observed in the study control group, as
in the 12-month exposure/12-month control group, the p-value for
the initial one-sided Fisher's exact test comparing the control and
highest dose groups would have been 0.1034; the two-sided
Fisher's exact test would have had a p-value of 0.2068; and the
test for the full study would have had a p-value of 0.0708. Similarly,
if four and not ﬁve rats in the 160 ppm dose group had been
observed with adenocarcinomas but no rats in the control group
had one, the Fisher's exact tests would have p-values of 0.0594 and
0.1187, respectively, for the one-sided and two-sided tests
comparing the highest exposure group to the control group and
0.0586 for the test comparing all exposure groups.
The power of the Fisher exact test is lower than others because it
does not incorporate any supplementary information that may be
available. For example, it ignores survival time differences between
groups. By accounting for each individual rat's “time at risk”,
Poisson regression can be used to estimate and compare the rate of
occurrences, i.e., the number of counted cases per observation time
(Cameron and Trivedi, 2005; Rothman et al. 2008). Exact Poisson
regression analysis, which is based on a permutation approach,
provides valid results for small samples (Hirji, 2006; Rothman et al.
2008).
Because not all of the animals survived the full period of the
study, the time each was at risk to develop an adenoma or an
adenocarcinoma varied. To adjust for these differences in exposure
time, survival time was incorporated in an exact Poisson regression
comparing the highest dose and the control groups resulted in a
two-sided p-value of 0.0657. Thus, incorporating survival time into
the analysis did not increase the statistical evidence of an effect.
1.3. Peto test
The Peto test (see Heimann and Heuhaus, 2001) considers not
only the incidence of adenocarcinomas, but also mortality due toMean life time unit Adenomas Adenocarcinomas
708.42 0 0
709.35 0 1
705.65 0 0
722.80 0 5
Table 2
Results from Fisher's exact test for the D5 24-month exposure study.
Test p-value for tests of equality of proportions with adenocarcinomas
All dose levels 0.0166
Excluding highest dose level (160 ppm) >0.9999
Control vs. 160 ppm dose group 0.0573
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rat had an adenoma/adenocarcinoma, the time to death and the
grade of each lesion (incidental, fatal or mortality independent) are
incorporated in the analysis. For lesions with a combination of
grades, the observed, expected and variance terms were calculated
for the incidental, fatal, and mortality independent grades sepa-
rately and then combined to produce an overall test statistic and
associated p-value. Based on the Peto test, the effect of exposure
level was signiﬁcant at the 5% level (Jean et al. 2015).Table 3
Poly-k max trend test using all dose levels and all but the highest level.
Tumor type p-values all dose levels p-values excluding
highest dose level
Bootstrap Asymptotic Bootstrap Asymptotic
Adenocarcinoma 0.00172 0.00077 0.30214 0.378911.4. Max poly-k trend test
Instead of assuming the cause of death is known as in the Peto
test, the poly-k test simply assumes that the time of death is known
(Bailar and Portier,1988). In general, this test is useful when there is
a control group and G treated groups, where the ith group receives
treatment dose zi, i ¼ 0, 1,…, G. Let pi be the probability an animal
in group i develops a tumor. Consider the null and alternative hy-
potheses H0 : p1 ¼ p2 ¼/ ¼ pG versus H1 : pi ¼ aþ b di for
some b > 0, where it is assumed there are G doses with
d1 < d2 </<dG. That is, the assumption is that the incidence rate is
an increasing linear function of the dose. If the incidence rate is not
linear, but instead increases only for the highest dose level as
suggested by Fisher's exact test, this test will not be as powerful.
The following notation will be used.
ni ¼ number of animals at risk in the ith group
di ¼ number of animals with the response of interest in the ith
group
ei ¼ expected number with response of interest in the ith group
For the CochraneArmitage test (Armitage 1955), it is assumed
that all animals are at equal risk of developing a tumor over the
duration of the study. If the risk varies over the duration of the
study, time strata can be formed so that the risk is equal within a
stratum. For the poly-k test, the following modiﬁed proportion is
tested for trend:
ri ¼
di
n*i
where
n*i ¼
Xni
j¼1
wij;
given theweight assigned at age of death to the jth animal in the ith
group is
wij ¼
(
1; if the jth animal in the ith group dies with a tumor
tij

tmax
k
; otherwise
and tij is the survival time and tmax is the maximum survival time.
The weights wij reﬂect the observation that tumors often appear at
the rate of a third-to ﬁfth-order polynomial in time (see Portieret al., 1986). Bailar and Portier (1988) recommended the use of
k¼ 3, resulting in the poly-3 trend test, which has become standard
and is used here. Noting that n*i is a random variable, Bieler and
Williams (1993) recommended an adjustment to the variance,
which is also adopted here.
The isotonicmodiﬁcation of the poly-3 test uses the same poly-3
correction, but the alternative hypothesis is
H2 : p1  p2 /  pG
with at least one strict inequality (Peddada et al. 2005). This test is
more appropriate than the poly-3 test when the response is
nonlinear with respect to dose. For example, if increasing exposure
levels does not affect the response below a certain threshold
exposure level, but does have an effect above that threshold value,
the response is nonlinear, and this test is more powerful.
Peddada et al. (2007) proposed combining the two test statistics,
WBW from the linear trend test and WISO from the isotonic trend
test, to testH0 versus (H1 orH2). The overall test statistic for themax
poly-k trend test is then
M1 ¼ maxfWBW ; WISOg (1)
Because M1 > 0 and large positive values represent deviations
from H0, the one-sided p-value is.
p ¼ PrH0ðM1  MobsÞ:
To ﬁnd the one-sided p-value, Peddada et al. (2007) considered
the asymptotic distribution of the test statistic and Casella et al.
(2012) used bootstrapping. Both approaches are considered here.
Ten thousand simulations of the asymptotic distribution and
10,000 bootstrap samples were drawn for each test. Because the
bootstrap distribution was anticipated to be skewed, the quantiles
of the empirical bootstrap distributionwere used to establish the p-
value of each test.
The results including all dose levels and then all but the highest
dose levels are presented in Table 3. Note that with the highest dose
level included, the incidences of adenocarcinomas are highly
signiﬁcantly different, but neither are close to being signiﬁcant
when the highest dose level is not included. Further, although the
conclusions are the samewhen using either the bootstrap approach
or the asymptotic distribution of the test statistic, the p-values
differ when rounding to the ﬁrst signiﬁcant digit. This might war-
rant further study.
1.5. Probit analysis
An alternative to the previous analyses is to consider a probit
analysis of the study where the model reﬂects the design as in
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rat k receiving dose i. Then
zik  Bernoulli ðpikÞ
and
probitðpikÞ ¼ mþ bwi þ gtik (2)
where
pik ¼ probability of a tumor for rat k in dose group i
m ¼ overall mean
b ¼ treatment effect
tik ¼ the cube of the proportion of time that rat k in dose group i
was alive in the study
g ¼ time effect
wi ¼ 0, 1, 4, and 16 for dose group i ¼ 0, 10, 40 and 160,
respectively
As in the poly-3 trend test, the use of the cube of the time that a
rat is alive in the study reﬂects the fact that tumors often appear at
the rate of a third-to ﬁfth-order polynomial in time.
If the incidence of tumors does not change with dose level, the
value of b would be 0 in model (2). As with the poly-3 trend test, if
the response increases in a nonlinear manner as suggested by each
of the preceding analyses, then the power associated with this test
of a linear effect will be less than if a linear trend was present.
A Bayesian analysis was conducted (Lee, 2003). Normal priors
with a mean of 0 and a variance of 4 were used for m, b, and g. The
Gibbs sampler had a burn-in of 10,000 iterations, a thinning rate of
300, and 10,000 recorded samples (Gelfand et al. 1990).
Because the posterior distribution of b is skewed, a credible
interval was used to assess whether 0 is a plausible value for the
treatment effect b. The 95% credible interval on b does not include
0 (see Table 4). Thus, when considering all dose levels, the effect of
dose is signiﬁcant when considering the incidence of adenocarci-
nomas. However, if the highest dose of 160 ppm D5 is not included
in the analysis, the treatment effect is not signiﬁcant.
The prior for b has amean of 0 and a variance of 4, placing 95% of
the prior probability to bs between 4 and 4. This represents a
relatively ﬂat prior, which is appropriate because no earlier studies
of the long-term effects of D5 had been conducted so the data
should dominate in the analysis. To ensure that the inferences with
respect to b are not sensitive to the choice of prior, a more infor-
mative prior normal distributionwith a mean of 0 and a variance of
1 was also considered. Some shrinkage of the point estimates of the
bs that were not signiﬁcantly different from 0 was observed.
However, the point estimate of b for incidence of adenocarcinoma
was 0.096 for standard deviations of 2 and 1. Most importantly, the
inferences concerning the signiﬁcance of b did not change in any
case.
1.6. Concurrent and historical controls
Based on the initial ﬁndings, researchers began working to
identify a biological mechanism to explain the increased incidenceTable 4
Assessment of the effect of dose, b, relative to the incidence of adenocarcinomas from Pr
Tumor type Dose levels (ppm) Mean Standard deviat
Adeno-carcinoma 0, 10, 40, 160 0.096 0.035
0, 10, 40 0.359 0.405of uterine endometrial adenocarcinomas at high levels of chronic
D5 exposure, but only slight responses, if any, in various in vitro and
in vivo test systems have been observed. This naturally led to the
question as to whether the ﬁnding could be spurious. At terminal
sampling, a complete necropsy was performed on all animals (see
the companion paper Jean et al. 2015 for details). The subsequent
measurements made on each animal resulted in a comparison of
the treatment groups for each of 129 response variables, making it
highly likely that some results would be declared signiﬁcant if no
effort is made to control the false discovery rate. The incidence of
endometrial adenocarcinomas in the uterus of F344 rats was
believed to be low, based on the review of the NTP data on F344 rats
(Haseman et al., 1998). Thus, large numbers of observations are
required for precise estimation. To address this concern, additional
concurrent and historical controls were used in a re-analysis of the
data (Tarone, 1982; Haseman, 1995; EPA, 2005).
For the Fischer 344 rat, uterine endometrial adenomas and ad-
enocarcinomas have been considered to be rare, typically less than
1% at 24months of age (Maekawa et al., 1983; Haseman et al., 1998)
and increasing to 8e12% at 30 months (Nyska et al., 1994). How-
ever, more recently published information on control groups
challenge the rareness of these tumors in Fischer 344 rats. Nyska
et al. (1994) observed signiﬁcant differences in tumor marker in-
cidences between two groups of unexposed female Fischer-344 rats
associated with studies conducted in the same laboratory, under
similar conditions, but separated by three years in time. Kuroiwa
et al. (2013) reported the incidence of uterine adenocarcinomas
in control groups of Fischer 344 rats from chronic bioassays from
studies in 1990e1999, 2000e2004 and 2005e2009 to be 3.3%,
12.0%, and 13.5%, respectively. The incidence of uterine adenocar-
cinomas has been observed to be greater in F344/CrlBr rats (mean
of 8% based on Charles River data, 1990 compilation) than in the
F344/N rats (0.7% in NTP feeding studies reported by Haseman
et al., 1998). Dinse et al., 2010, conﬁrmed the incidence of uterine
adenocarcinoma was 0.22% in Fischer 344/N rats. Thus, based on
the recent literature, the spontaneous tumor incidences are
different for different sub-strains of Fischer 344 rats, and the in-
cidences in sub-strains can change with time. In selecting the
control groups for the re-analysis, the studies used the same sub-
strain and were conducted over a narrow span of time.
As noted in the section “Initial Analyses,” in parallel of the
subgroup (D) experiencing a 24-month exposure protocol another
subgroup (C) experienced another 24-month exposure protocol,
consisting of 12 months of exposure followed by12 months of re-
covery period. For the non-exposed control animals in the latter
subgroup, this corresponds to 12 months of air-exposure followed
by 12months of non-exposure in the recovery phase. Thus, the only
difference in the two subgroups is the second 12 months in which
one subgroup continued to be placed in the test chamber (with no
exposure) according to the study protocol and the other remained
in their home cage. Obviously the conditions for the control animals
of subgroup C come very close to the conditions for the control
animals of subgroup D; closer than is possible for any other control
group not being part of the same study in the same laboratory at
the same time as is the case here.
One may argue that the differences in handling in the secondobit model.
ion Percentile of posterior distribution
2.5 5 50 95 97.5
0.034 0.043 0.094 0.156 0.171
1.325 1.112 0.299 0.198 0.281
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could then be combined for analysis. However, this slight difference
and the fact that, consistent with the design, the two groups were
treated as two separate groups throughout the study result in the
groups being contemporary historical control data (OECD, 2012,
Sections 394e395). Consequently, when they are included in an
analysis, any additional heterogeneity that may be associated with
the inclusion of that control group is explicitly accounted for in the
analysis, just as it is with the historical controls.
Great care should be exercised when selecting historical control
groups for inclusion in the analysis of a study. “When historical
control data are used, the discussion should address several issues
that affect comparability of historical and concurrent control data,
such as genetic drift in the laboratory strains, differences in pa-
thology examination at different times and in different laboratories
(e.g., in criteria for evaluating lesions; variations in the techniques
for the preparation or reading of tissue samples among labora-
tories), and comparability of animals from different suppliers. The
most relevant historical data come from the same laboratory and
the same supplier and are gathered within 2 or 3 years one way or
the other of the study under review; other data should be used only
with extreme caution.” (EPA, 2005, p. 48).
In addition to the 12-month exposure/12-month recovery con-
trol group in the D5 study, historical control groups from three
additional studies, each of 24-month duration, were considered:
Octamethylcyclotetrasiloxane (D4) (Lee, 2004), Hexamethyldisi-
loxane (HMDS) (Dotti et al. 2005), and Polydimethylsiloxane
(PDMS) (Mertens, 2003). Each of the studies had a 12-month
exposure/12-month recovery and a 24-month exposure control
group, both of which were considered as a potential historical
control. All studies used the Fischer-344 rats of the same sub-strain
from the same source (see Table 5). All rats were received from the
source within 28 months of the start of the D5 study, and all but the
HMDS study controls were received within 13 months of study
initiation. Further, the rats were all of a similar age. The studies
were all conducted by Dow Corning. However, the testing facilities
varied within and among studies. This source of variation must be
accounted for in the analysis.
The control groups were comprised of 20e65 animals that had
little to no incidences of adenomas/adenocarcinomas (see Table 6).
To further assess the appropriateness of including these historical
control groups, the mortality and a set of markers for tumor inci-
dence were compared among the control groups and speciﬁcally
between the D5 24-month exposure and each of the other control
groups. The markers for tumor incidence were spleen mononuclear
cell leukemia, pituitary P. Distalis adenoma, thyroid gland c-cell
adenoma, uterine stromal polyps, and mammary gland
ﬁbroadenoma.1.7. Control group mortality
From Table 7, the survival rates among control groups are notTable 5
Characteristics of the control groups.
Control group Source Strain/sub
D4 12 exposure/12 recovery Charles River F344/CrlB
D4 24-month exposure Charles River F344/CrlB
D5 12 exposure/12 recovery Charles River F344/CrlB
D5 24-month exposure Charles River F344/CrlB
HMDS 12 exposure/12 recovery Charles River F344/CrlB
HMDS 24-month exposure Charles River F344/CrlB
PDMS 12 exposure/12 recovery Charles River F344/CrlB
PDMS 24-month exposure Charles River F344/CrlBsigniﬁcantly different (p¼ 0.3498 using Fisher's exact test). Yet, this
test does not consider the time that each rat survives, only whether
or not it is alive at the end of the study. The product-limit estimate
of the survival function considers the additional information of
survival time and the fact that a rat that is alive at study's end has
an unknown survival time. The estimated functions were compared
using the log-rank test and the Wilcoxon test and found to be
highly signiﬁcantly different (see Table 8). The plots of the esti-
mated survival functions are displayed in Fig. 1.
Although the ﬁnding that at least one of the survival functions
differs from the others is important, primary interest lies in
assessing the difference, if any, between the survival function of the
D5 24-month exposure control group and the survival function of
each potential historical control. Thus, the survival functions of the
other seven control groups were compared to the D5 24-month
exposure control group (see Table 9). Recall that this analysis
compares survival functions and thus considers all information on
time of death. For animals that survived, it is known that they have
survived until the study's end, but it is unknown howmuch longer
they could have survived. This helps explain the result that both
HMDS groups separate so clearly from the others, given that the
proportions of rats surviving until the end of the study for the
HDMS groups are similar to the proportions for the PDMS control
groups. Consider the control groups from these two studies. The
earliest death in the HMDS group was on May 20, 1999, just a little
more than 3 months prior to the study's termination at the end of
August, 1999. In contrast, the earliest death in the PDMS groupswas
on February 14, 2000, a little more than 9 months prior to the
study's conclusion about November 20, 2000. These comparatively
earlier deaths for some PDMS rats relative to the HMDS rats
contributed to the projections that the PDMS groups would tend to
have a shorter survival time than the HMDS groups. It may also be
important that the HMDS study was conducted more than a year
earlier than any of the other studies.
In summary, both HMDS control groups have signiﬁcantly
longer survival times than the D5 24-month exposure control
group. The other control groups do not have signiﬁcantly different
survival times than the D5 24-month control group. We note that a
non-signiﬁcant test result does not establish equivalence (Hauck
and Anderson, 1984).1.8. Control group tumor incidence
The following tumors represent a selected group of neoplastic
lesions that are commonly observed in control animals in chronic
bioassays: pituitary P. Distalis adenoma, thyroid gland c-cell ade-
noma, uterine stromal polyps, and mammary gland ﬁbroadenoma.
Their use here affords a generalized selection of well recognized
neoplastic lesions for comparison among the individual chronic
bioassay studies of interest. If a set of controls differs signiﬁcantly
from each other, and more speciﬁcally from the D5 24-month
exposure control group, then it may not be an appropriate-strain Date of animal receipt Age at start of study
R 1/12/1999 7e8 weeks
R 1/12/1999 7e8 weeks
R 12/1/1999 6 weeks
R 12/1/1999 6 weeks
R 8/20/1997 6 weeks
R 8/20/1997 6 weeks
R 11/3/1998 7e8 weeks
R 11/3/1998 7e8 weeks
Table 6
Incidence of adenomas/adenocarcinomas in the control groups.
Control group Number of animals Adenoma Adenocarcinoma Combined
D4 12 exposure/12 recovery 20 0 0 0
D4 24-month exposure 59 0 0 0
D5 12 exposure/12 recovery 20 0 1 1
D5 24-month exposure 60 0 0 0
HMDS 12 exposure/12 recovery 20 0 1 1
HMDS 24-month exposure 65 1 1 2
PDMS 12 exposure/12 recovery 20 0 0 0
PDMS 24-month exposure 60 2 0 2
Table 7
Survival rates within control groups.
Treatment Total Deaths Survivals Percent survival
D4 12 exposure/12 recovery 20 6 14 70.00
D4 24-month exposure 60 17 43 71.67
D5 12 exposure/12 recovery 20 6 14 70.00
D5 24-month exposure 60 14 46 76.67
HMDS 12 exposure/12 recovery 20 3 17 85.00
HMDS 24-month exposure 65 11 54 83.08
PDMS 12 exposure/12 recovery 20 3 17 85.00
PDMS 24-month exposure 60 8 52 86.67
Totals 325 68 257 79.08
Table 8
Results from testing equality of 8 survival functions.
Test of equality over treatments
Test Chi-square DF Pr > Chi-Square
Log-Rank 31.5471 7 <0.0001
Wilcoxon 30.9812 7 <0.0001
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that are positive and negative for thesemarkers within each control
group are displayed in Tables 10e14. Note that, in some cases, a
measurement(s) could not be made on an animal so some data are
missing, resulting in the total number of observations being lessFig. 1. Plot of negative log of the estimated surthan the number of rats within the group. It is assumed that these
data are missing at random.
Fisher's exact test was used ﬁrst to compare all control groups
for each of themarkers of tumor incidence (Table 15) and then to do
pairwise comparisons with the D5 24-month exposure control
group (Table 16). Although some indication of differences among
groups was found for spleen mononuclear cell leukemia, pituitary
P. Distalis adenoma, and mammary gland ﬁbroadenoma, in each
case, the key comparison is with the D5 24-month exposure control
group. When making these comparisons, the only concerns for
differences are raised for the P. Distalis adenoma, which tended to
be higher for the D4 24-month exposure, PDMS 24-month expo-
sure, and the PDMS 12-month exposure/12-month recovery control
groups.1.9. Summary of control group ﬁndings
Some indications of differences have been found between the
D5 24-month exposure control group and the D4 24-month
exposure control group and each of the PDMS control groups.
However, as the number of tests increases, the probability of a false
positive, also called a false discovery, increases. The Benjamini-
Hochberg procedure (BH step-up procedure) (Benjamini and
Hochberg, 1995) controls the rate of false positives at a speciﬁed
level, say a. To conduct the procedure form hypothesis tests, the p-
values for the tests are ordered from smallest to largest:
p(1) p(2)… p(m). Note: The parentheses are used to denote thevival function from seven control groups.
Table 9
Comparison of mortality in control groups to D5 24-month exposure control group.
Test of equality with D5 24-month exposure control group
Control group Logerank test Wilcoxon test
Chi-square DF Pr>Chi-square Chi-square DF Pr>Chi-square
D5 12 Exposure/12 Recovery 0.5572 1 0.4554 0.5678 1 0.4511
D4 24-Month Exposure 0.3337 1 0.5635 0.2932 1 0.5882
D4 12 Exposure/12 Recovery 1.2299 1 0.2674 1.3697 1 0.2419
HMDS 24-Month Exposure 17.0695 1 <0.0001 17.0040 1 <0.0001
HMDS 12 Exposure/12 Recovery 5.2677 1 0.0217 5.2400 1 0.0221
PDMS 24-Month Exposure 1.8324 1 0.1758 1.6969 1 0.1927
PDMS 12 Exposure/12 Recovery 0.4985 1 0.4802 0.4048 1 0.5246
Table 10
Observed incidences of spleen mononuclear cell leukemia for all control groups.
Control group Positive Negative Percent positive
D4 12 exposure/12 recovery 6 14 30.0
D4 24-month exposure 14 45 23.7
D5 12 exposure/12 recovery 3c 17 15.0
D5 24-month exposure 13c 47 21.7
HMDS 12 exposure/12 recovery 5c 15 25.0
HMDS 24-month exposure 10c 55 15.4
PDMS 12 exposure/12 recovery 7d 13 35.0
PDMS 24-month exposure 12d 48 20.0
c Hemolymphoretic system used for “spleen”.
d Large granular lymphocyte leukemia (under “organ” systemic tumors).
Table 11
Observed incidences of pituitary P. Distalis adenoma for all control groups.
Control group Positive Negative Percent positive
D4 12 exposure/12 recovery 5 15 25.0
D4 24-month exposure 27 31 46.6
D5 12 exposure/12 recovery 5 15 25.0
D5 24-month exposure 12 48 20.0
HMDS 12 exposure/12 recovery 7 13 35.0
HMDS 24-month exposure 18 46 28.1
PDMS 12 exposure/12 recovery 9 11 45.0
PDMS 24-month exposure 22 37 37.3
Table 12
Observed incidences of thyroid gland C-Cell adenoma for all control groups.
Control group Positive Negative Percent positive
D4 12 exposure/12 recovery 3 17 15.0
D4 24-month exposure 4 55 6.8
D5 12 exposure/12 recovery 0 20 0.0
D5 24-month exposure 4 56 6.7
HMDS 12 exposure/12 recovery 1 19 5.0
HMDS 24-month exposure 2 63 3.1
PDMS 12 exposure/12 recovery 1 19 5.0
PDMS 24-month exposure 5 55 8.3
Table 13
Observed incidences of uterine stromal polyps for all control groups.
Control group Positive Negative Percent positive
D4 12 exposure/12 recovery 1 19 5.0
D4 24-month exposure 11 48 18.6
D5 12 exposure/12 recovery 3 17 15.0
D5 24-month exposure 10 50 16.7
HMDS 12 exposure/12 recovery 6 14 30.0
HMDS 24-month exposure 17 48 26.2
PDMS 12 exposure/12 recovery 2 18 10.0
PDMS 24-month exposure 16 44 26.7
Table 14
Observed incidences of mammary gland ﬁbroadenoma for all control groups.
Control group Positive Negative Percent positive
D4 12 exposure/12 recovery 3a 17 15.0
D4 24-month exposure 13a 46 22.0
D5 12 exposure/12 recovery 2 17 10.5
D5 24-month exposure 8 52 13.3
HMDS 12 exposure/12 recovery 0 20 0.0
HMDS 24-month exposure 4 61 6.2
PDMS 12 exposure/12 recovery 1 19 5.0
PDMS 24-month exposure 2 57 3.4
a This value is composed of both diagnoses: Fibroadenoma þ Fibroadenoma,
multiple.
Table 15
Fisher's exact test comparing tumor incidence across all control groups.
Tumor type Test statistic p-value
Spleen mononuclear cell leukemia 6.286E-07 0.6026
Pituitary P. Distalis adenoma 5.922E-09 0.0684
Thyroid gland C-cell adenoma 3.131E-05 0.5920
Uterine stromal polyps 1.339E-07 0.2525
Mammary gland ﬁbroadenoma 3.862E-08 0.0180
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notes the p-value corresponding to the ith hypothesis. Here one test
for equality of survival rates and ﬁve for the equality of tumor
incidence have been conducted in comparing each control group to
the D5 24-month exposure control group. Thus, m is equal to six.
The procedure is performed as follows:
1. For a given a, ﬁnd the largest k such that p(k)  ka/m ¼ 0.05 k/
6 ¼ 0.00833 k.
2. Reject all hypotheses (declare positive discoveries) for all H(i),
i ¼ 1, 2, …, k.
Using the BH step-up procedure, the D4 24-month exposure
control group is found to have a signiﬁcantly higher incidence of
pituitary P. Distalis adenoma than the D5 24-month exposure
control group. Further, the HMDS 24-month exposure control
group is found to have signiﬁcantly higher survival rates than the
D5 24-month exposure control group, but the differences in the
incidences of pituitary P. Distalis adenoma between the D5 24-
month exposure and either the PDMS 24-month or the PDMS 12-
month exposure/12-month recover control groups are not signiﬁ-
cant. Further, the survival rates for the HMDS 12-month exposure/
12-month recovery control group are not signiﬁcantly different
from those for the D5 24-month exposure control group. Thus, we
found a signiﬁcant heterogeneity in response between different
groups of Fischer-344 control rats although all rats were received
within 28 months of the start of the D5 study from the same
Table 16
Comparison of Tumor Incidence in Control Groups to D5 24-Month Exposure Control Group: Fisher's Exact Test p-values.
Control group Spleen Mononuclear cell
leukemia
Pituitary P. Distalis
adenoma
Thyroid gland C-Cell
adenoma
Uterine stromal
polyps
Mammary gland
ﬁbroadenoma
D5 12 Exposure/12 Recovery 0.7485 0.7533 0.5673 >0.9999 >0.9999
D4 24-month exposure 0.8294 0.0031 >0.9999 0.8140 0.2378
D4 12 exposure/12 recovery 0.5456 0.7533 0.3582 0.2750 >0.9999
HMDS 24-month exposure 0.4890 0.3042 0.4259 0.2768 0.2286
HMDS 12 exposure/12
recovery
0.7634 0.2257 >0.9999 0.2107 0.1906
PDMS 24-month exposure >0.9999 0.0438 >0.9999 0.2677 0.0946
PDMS 12 exposure/12
recovery
0.2466 0.0401 >0.9999 0.7203 0.4375
L.J. Young, P. Morfeld / Regulatory Toxicology and Pharmacology 74 (2016) S14eS24 S21supplier and although all rats were of the same sub-strain.
Based on these results, it was decided to conduct four sets of
analyses, each with a different set of controls (see Table 17). The
ﬁrst is simply the concurrent controls, which have already been
considered. The other sets are increasingly heterogeneous, allowing
the impact of this heterogeneity to be explored. The second set
includes both the D5 12-month exposure/12-month recovery and
the concurrent control groups. The D5 12-month exposure/12-
month recovery control group was in the same D5 study. They
were treated as a group distinct from the 24-month exposure
control group during the study. This and the small differences in
handling discussed earlier make it necessary for them to be treated
as contemporary historical controls. Consequently, this control
group is not simply combined with the D5 24-month exposure
control group for analysis. Instead, the potential additional het-
erogeneity due to the differences in handling is explicitly accounted
for. The third set includes the two D5 study control groups as well
as the control groups that were not signiﬁcantly different from the
D5 24-month exposure control group with respect to survival rate
or the incidences of any of the ﬁve selectedmarkers for tumors. The
ﬁnal set of control groups included all of those in set 3 as well as the
control groups that had signiﬁcantly different survival rates or tu-
mor incidence of a marker tumor from the D5 24-month exposure
control group. Thus, each set reﬂects increasing heterogeneity
among the control groups.
A basic assumption in all scientiﬁc studies is that of exchange-
ability. Here the assumption implies that rats receiving the highest
dose have the same susceptibility to adenocarcinomas as rats in the
control group. The randomization of the rats to exposure levels in
the D5 24-month exposure study provides a foundation for making
the exchangeability assumption in that each rat was equally likely
to have been in any exposure group. Further, for the full D5 study,
rats were also randomized to subgroups. Thus, the assumption of
exchangeability is also reasonablewhen including the D512-month
exposure/12-month recovery group as a concurrent historical
control. Because the other historical control groups were not sub-
ject to the randomization process for the study of interest, the
question of whether the rats are truly exchangeable can be raised.
To rely on exchangeability, one must rely on a biological argument.
All control groups considered here were from the same source,Table 17
Sets of control groups.
Set Study control groups
1 D5 24-month exposure
2 D5 24-month exposure; D5 12-month exposure/12-month recovery
3 D5 24-month exposure; D5 12-month exposure/12-month recovery; D4 12-month
PDMS 24-month exposure; PDMS 12-month exposure/12-month recovery
4 D5 24-month exposure; D5 12-month exposure/12-month recovery; D4 12-month
PDMS 24-month exposure; PDMS 12-month exposure/12-month recovery; D4 24-strain, and sub-strain. They were also of similar ages at study onset.
Yet, signiﬁcant differences were found among them. This could be
due to differences in laboratories in which the studies were con-
ducted or to other study differences. Further, as discussed earlier,
the signiﬁcant differences could be due to drift in the strain over
time. Thus, as control set 3 and then set 4 is added to the analysis,
the question as to whether the assumption of exchangeability is
met becomes an increasing concern.
1.10. Analyses incorporating historical controls
When adding historical controls, it is important to account for
the additional heterogeneity introduced when incorporating them
into the analyses. Three such analyses are considered in this paper.
The ﬁrst is Fisher's exact test. The second is an extension of the max
poly-k trend test discussed earlier. The ﬁnal one is a meta-analysis
developed by Casella et al. (2012).
1.11. Fisher exact test
Fisher's exact test can be used to test whether the proportion of
observations with a positive response is the same for each of t
treatment groups, given the number of observations for each
treatment and the total number of positive responses. As when
considering only two treatment groups, the p-value of the test can
be determined exactly and does not depend on asymptotic (large
sample) theory. Control groups within each set were compared
with respect to the incidence of adenocarcinomas. In no case was
there a signiﬁcant difference. To account for heterogeneity associ-
ated with different groups of control animals, the control groups
were treated as separate groups in all analyses.
As with the initial analysis, a preliminary test of the control
groups versus the 160 ppm exposure group was conducted ﬁrst
using each set of controls (see Table 18). Here the Fisher exact test
weights each of the control groups equal to the exposure group so
the test is not only comparing exposure and control groups but also
control groups within the same set. The difference in incidences in
controls and the highest exposure level was not signiﬁcant for the
ﬁrst two sets of controls (set 1, the control group associated with
the D5 24-month exposure study and set 2, the control groupsexposure/12-month recovery; HMDS 12-month exposure/12-month recovery;
exposure/12-month recovery; HMDS 12-month exposure/12-month recovery;
month exposure; HMDS 24-month exposure
Table 18
p-Values From Fisher's exact test of constant proportions. Using all dose levels and
all but the highest level.
Control set Dose levels (ppm) Adenocarcinoma
Set 1 0, 160 0.0573
0, 10, 40, 160 0.0166
0, 10, 40 >0.9999
Set 2 0, 160 0.0659
0, 10, 40, 160 0.0173
0, 10, 40 0.1905
Set 3 0, 160 0.0313
0, 10, 40, 160 0.0188
0, 10, 40 0.1554
Set 4 0, 160 0.0078
0, 10, 40, 160 0.0188
0, 10, 40 0.1554
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above the 0.05 level. However, for control sets 3 and 4, the effect of
the highest level of exposure was signiﬁcant.
Consider the cases where the difference between control groups
and the highest exposure level is signiﬁcant or close to being sig-
niﬁcant (as in the cases of p-values of 0.0573 and 0.0659).When the
full study is analyzed, the effect of exposure is found to be signiﬁ-
cant when the highest dose is included and is not signiﬁcant when
it is not included (see Table 18).
Although not presented here, an analysis with similar results
could be conducted using exact Poisson regression.1.12. Extended max poly-K trend test
The max poly-k trend test compares the tumor rates in the
control and treatment groups using information from (1) the poly-3
extension to the CochraneArmitage linear trend test with the
Bieler-Williams variance adjustment and (2) the isotonic trend test.
Recall that themax poly-k trend test statistic is themaximum of the
test statistics from these two tests. For the extended max poly-k
trend test, Peddada et al. (2007) proposed using the maximum of
two test statistics. The ﬁrst isM1 of themax poly-k trend test, which
incorporates only the current control group as in (1). The second is
M2, which is analogous to M1, except that it is based on the his-
torical control groups and reﬂects their heterogeneity. Then, the
test statistic is M ¼ max(M1, M2). As in Casella et al. (2012), boot-
strap methods were used to determine the one-sided p-values
associated with each test.
The incidence of adenocarcinoma is signiﬁcant if the 160-ppm
dose level is included, and it is not signiﬁcant if the 160-ppm
dose level is not included (Table 19). Thus, for this test, the high-
est dose group is driving the conclusion of a highly signiﬁcant ef-
fect, and the conclusion does not depend onwhich set of controls is
used.Table 19
p-Values from poly-k max trend test of constant proportions using all dose levels
and all but the highest level.
Control set Dose levels (ppm) Adenocarcinoma
Set 1 0, 10, 40, 160 0.0017
0, 10, 40 0.3021
Set 2 0, 10, 40, 160 0.0017
0, 10, 40 0.6218
Set 3 0, 10, 40, 160 0.0017
0, 10, 40 0.5043
Set 4 0, 10, 40, 160 0.0014
0, 10, 40 0.47341.13. Meta-analysis
Another approach to accounting for the heterogeneity intro-
duced by using the historical controls is to include that source of
variability in the probit analysis considered earlier. To do this, again
let zijk be the 0/1 (no tumor/tumor) response of rat k receiving dose i
in study j. As before,
zijk  Bernoulli

pijk

but the model becomes
probit

pijk

¼ mþ bwiIðj ¼ 0Þ þ sj þ gtik (3)
where
pijk ¼ probability of a tumor for rat k in dose group i
m ¼ overall mean
b ¼ treatment effect
wi ¼ 0, 1, 4, and 16 for dose group i ¼ 0, 10, 40 and 160,
respectively
sj  Nð0; s2sj Þ ¼ random effect of jth study
tijk ¼ the cube of the proportion of time that rat k in dose group i
was alive in the study
g ¼ time effect
The indicator function I(j ¼ 0) reﬂects the fact that dose levels
other than the control (0 ppm) are only considered for the current
study. The prior distribution for sj
m; s2s was Nðm; s2s Þ. Normal priors
with a mean of zero and a variance of four were used for m, b, and g.
The prior distribution of s2s was exponential with a mean of two.
The Gibbs sampler had a burn-in of 10,000 iterations, a thinning
rate of 300, and 10,000 recorded samples.
As with the original probit analysis, interest lies in whether or
not there is a treatment effect. Thus, the test of interest is of H0:
b ¼ 0 versus H1: b s 0. The mean and standard deviation of the
posterior distribution as well as percentiles of the posterior dis-
tribution were computed for each set of historical controls (see
Table 20). The 2.5 and 97.5 percentiles correspond to a test of the
hypotheses at the 5% level. If both endpoints are positive (or
negative), the null hypothesis is rejected, and the conclusion is that
the incidence of tumors increases (decreases) with dose. To ensure
that the inferences on b are not sensitive to the choice of prior, a
prior with amean of zero and a variance of onewas also considered.
The results did not change in any meaningful way.
Regardless of which set of controls is used in the analysis, the
conclusions are the same and agree with the results based solely on
concurrent controls. (Note: In reviewing the results of Casella et al.,
2012 in the context of this work, a small programming error was
found in the code. This was corrected with the help of those au-
thors, and the results presented here reﬂect the revised code.) The
effect of D5 is signiﬁcant for adenocarcinomas. However, if the
highest dose of 160 ppm is excluded from the analysis, the effect of
D5 is not signiﬁcant, not even marginally so.2. Discussion
Five uterine endometrial adenocarcinomaswere observed in the
highest dose group of 160 ppm. Only one was found in the other
dose groups, and it was in the lowest positive dose group of 10 ppm.
When using Fisher's exact test for testing the effect of exposure, the
incidence of adenocarcinomas in the highest dose group compared
to the control group was either signiﬁcantly different or close
(p ¼ 0.0572 or 0.0659) to being signiﬁcantly different from the
Table 20
Assessment of the Effect of Dose, b, Relative to the incidence of adenocarcinomas from Probit model using various control sets.
Tumor type Dose Levels (ppm) Mean Standard deviation Percentile of posterior distribution
2.5 5 50 95 97.5
Control 0, 10, 40, 160 0.077 0.030 0.023 0.031 0.075 0.128 0.140
Group 2 0, 10, 40 0.451 0.410 1.422 1.234 0.385 0.084 0.157
Control 0, 10, 40, 160 0.084 0.028 0.032 0.040 0.083 0.133 0.144
Group 3 0, 10, 40 0.319 0.366 1.184 1.006 0.253 0.159 0.225
Control 0, 10, 40, 160 0.076 0.026 0.029 0.0370 0.075 0.121 0.131
Group 4 0, 10, 40 0.378 0.372 1.261 1.093 0.308 0.095 0.154
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signiﬁcant effect was observed when the high dose group was
included in the analysis, but the effect was not signiﬁcant when the
high dose group was not included. These results do not depend on
which test was used.
Fisher's exact test and the test based on exact Poisson regression
can be conducted using most major statistical software packages,
such as SAS, Stata and R. The Bayesian probit model was pro-
grammed using JAGS in R and could be programmed in other
software packages that accommodate Bayesian models. However,
this particular Bayesian model is somewhat challenging to imple-
ment and routine implementation would be facilitated by having a
specialized R package focusing on this type of model. Themax poly-
k trend test is based on newer methods and, to our knowledge,
software packages that can be used to conduct this test are not
readily available. As software does become more accessible, the
max poly k trend test and the Bayesian probit model will surely be
used more because they have better statistical properties and can
account for heterogeneity introduced when concurrent and his-
torical controls are used in the analysis.
Because the highest dose of D5 (160 ppm) is clearly driving the
signiﬁcant effects observed in these analyses, a threshold effect
may be present. Models can be used to estimate the threshold.
However, these are not explored here.
Jean et al. (2015) present a summary of the test results for 129
responses observed for the female rats in the 24-month inhalation
study (see Smith et al., 2005, for details). For seven responses, the
test could not be conducted due to insufﬁcient data. Among the 122
one-sided Fisher exact tests performed, two were signiﬁcant at the
5% level. One test indicated an increase and the other a decline in
response as the dose level increased. The comparison between
adenocarcinoma incidence for dose groups 160 ppm and 0 ppm,
which had a one-sided p-value from the Fisher exact test of 0.0287,
was the test resulting in a signiﬁcant increase in response. How-
ever, based on the Benjamini and Hochberg (1995) adjustment for
false discoveries, the ﬁrst and second smallest p-values associated
with the two tests that were signiﬁcant at the 5% level would need
to be less than 0.0002 and 0.0004, respectively, to be declared
signiﬁcant. In either case, the observed value of 0.0287 is not sig-
niﬁcant, if multiple testing is considered.
Given the large number of tests conducted in the study, the
question naturally rises as to whether the result could be simply a
chance ﬁnding. As with any statistical test, this is a possibility; the
p-value simply provides the probability of such a ﬁnding if there is
no effect. The evidence tends to support the conclusion that D5 at
the highest dose level results in an increased incidence of adeno-
carcinomas, but not adenomas. However, the biological investiga-
tion by Klaunig et al. (2015) addresses whether an excess is
plausible on mechanistic grounds and the potential biological
relevance.
As noted in the EPA (2005, p. 48) guidelines, “In cases where
there may be reason to discount the biological relevance to humans
of increases in common animal tumors, such considerations shouldbe weighed on their own merits and clearly distinguished from
statistical concerns.” To assess human relevance, besides the sta-
tistics, the whole toxicological proﬁle of the substance must be
considered in an overall evaluation.
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